Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Current Assets (2020 - 2025)

Historic Current Assets for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $530.6 million.

  • Mirum Pharmaceuticals' Current Assets rose 3723.21% to $530.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $530.6 million, marking a year-over-year increase of 3723.21%. This contributed to the annual value of $392.8 million for FY2024, which is 135.39% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Current Assets of $530.6 million as of Q3 2025, which was up 3723.21% from $453.4 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Current Assets high stood at $530.6 million for Q3 2025, and its period low was $147.2 million during Q2 2022.
  • Its 5-year average for Current Assets is $304.3 million, with a median of $367.8 million in 2024.
  • In the last 5 years, Mirum Pharmaceuticals' Current Assets crashed by 3552.24% in 2022 and then soared by 16046.25% in 2023.
  • Mirum Pharmaceuticals' Current Assets (Quarter) stood at $166.6 million in 2021, then rose by 14.19% to $190.2 million in 2022, then skyrocketed by 103.73% to $387.5 million in 2023, then grew by 1.35% to $392.8 million in 2024, then skyrocketed by 35.08% to $530.6 million in 2025.
  • Its Current Assets was $530.6 million in Q3 2025, compared to $453.4 million in Q2 2025 and $410.8 million in Q1 2025.